Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

M Zubair Jafar

Interventional Cardiology Poughkeepsie, NY Medical Doctor

NPI 1790758688 CMS profile 80612

1 Columbia St, Suite 200, Poughkeepsie, NY 12601

Open in the dashboard

General payments

$23,849

263 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$623,647 paid to institutions, not to them · program years 2020–2025

Through program year 2025, M Zubair Jafar of Poughkeepsie, NY is reported in the CMS Open Payments database as having received $23,849 across 263 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $623,647 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 78th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,553 51
2024 General $858 36
2023 General $346 15
2022 General $674 25
2021 General $493 22
2020 General $174 12
2019 General $17,751 102

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • M Zubair Jafar
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to M Zubair Jafar were reported at $3,553. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year M Zubair Jafar Interventional Cardiology median Middle half National median
2019 $17,751 $1,097 $329–$3,048 $163
2020 $174 $473 $161–$1,480 $114
2021 $493 $677 $233–$1,827 $132
2022 $674 $978 $333–$2,724 $149
2023 $346 $1,136 $382–$2,986 $160
2024 $858 $1,181 $395–$3,326 $164
2025 $3,553 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $9,764 10 payments
  2. Medtronic Vascular, Inc. $5,665 61 payments
  3. Edwards Lifesciences Corporation $4,463 31 payments
  4. Medtronic, Inc. $998 34 payments
  5. Abiomed $782 33 payments
  6. Novartis Pharmaceuticals Corporation $406 23 payments
  7. Abbott Laboratories $333 9 payments
  8. Amgen Inc. $309 16 payments
  9. Shockwave Medical, Inc $306 6 payments
  10. Boston Scientific Corporation $212 8 payments
  11. Other $612 32 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $13,100 6 payments
  2. Food and Beverage $6,407 250 payments
  3. Travel and Lodging $2,833 5 payments
  4. Honoraria $1,500 1 payment
  5. Education $9 1 payment
Products named General payments · program years 2019–2025
  1. XARELTO $9,764 10 payments
  2. CoreValve Evolut $5,457 47 payments
  3. EVOQUE $2,256 6 payments
  4. Edwards SAPIEN 3 Transcatheter Heart Valve $1,671 9 payments
  5. Impella $410 17 payments
  6. Repatha $266 14 payments
  7. LEQVIO $250 14 payments
  8. COREVALVE EVOLUT R $223 13 payments
  9. ENTRESTO $156 9 payments
  10. BRILINTA $135 10 payments
  11. Other $2,285 87 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 34 drugs

Part D claims

2,525

Median for Interventional Cardiology: 2,236

Drug cost

$491,214

Median for Interventional Cardiology: $380,412

Branded share of claims

26.9%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 141 $200,165
Entresto Sacubitril/Valsartan Brand 39 $57,393
Xarelto Rivaroxaban Brand 30 $47,602
Repatha Sureclick Evolocumab Brand 58 $46,221
Brilinta Ticagrelor Brand 37 $39,975
Repatha Pushtronex Evolocumab Brand 40 $38,420
Praluent Pen Alirocumab Brand 18 $10,543
Vascepa Icosapent Ethyl Brand 16 $7,916
Atorvastatin Calcium Generic 410 $6,383
Ranolazine Er Ranolazine Brand 36 $6,163

The 10 drugs with the highest cost, of 34 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 71 billing codes

Paid by Medicare

$331,972

Medicare's payments for the services billed

Medicare patients

1,708

Average age 77

Services billed

4,746

836 women, 872 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 71%
Arthritis 46%
Heart failure 45%
Diabetes 43%
Atrial fibrillation 43%
Chronic kidney disease 36%
COPD 31%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
  • Novartis Pharmaceuticals Corporation $72
$72 — —
Arcalyst
  • Kiniksa Pharmaceuticals International, plc $55
$55 — —
Repatha
  • Amgen Inc. $16
$16 109 —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $12
$12 39 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

263 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record